Chosa Oncology targets first US Platin-DRP test revenue in summer 2027

Bitget2026/11/04 09:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Chosa Oncology signed an agreement with a CLIA-certified laboratory to prepare its Platin-DRP lung cancer test for US commercialization.
First commercial revenue is targeted for summer 2027, subject to successful analytical validation and implementation under the laboratory’s CLIA certification.
Expected first-year sales total 300-500 tests, against an estimated US market potential exceeding 250,000 tests annually.
SPLENDOUR results presented in March 2026 linked higher Platin-DRP scores to longer survival and delayed disease progression in advanced lung cancer.
A Mount Sinai study evaluating the test with chemotherapy-immunotherapy combinations has received 94 tumor samples; initial results are expected in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 20261104:BIT:4609:0) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chosa Oncology targets first US Platin-DRP test revenue in summer 2027

You may also like

Crypto prices